ESR2 and melanoma: Recently, the synthetic non-steroidal estrogen and selective ERβ agonist LY500307 showed the capability to suppress melanoma lung metastasis in the B16 murine melanoma in vivo model by up-regulating innate immunity in a tumor microenvironment [55].